Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 783

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 783
---
the “

#### SPAC Merger
” and, together with the Company Merger, the “

#### Mergers
”).

### WHEREAS
, pursuant to the Mergers, the Sponsor and Liminatus Members were issued common stock, par value $0.0001 of ParentCo (“

#### Common Stock
”) and may be issued shares of Common Stock in the future pursuant to the terms of the Transaction Agreement;

### WHEREAS
, pursuant to the Mergers, Sponsor and Cantor were issued certain warrants to purchase Common Stock (the “

#### Warrants
”);

### WHEREAS
, ParentCo, SPAC and the Equity PIPE Subscribers have entered into that certain Subscription Agreement, dated as of November 28, 2022 (the “

#### Equity Subscription Agreement
”), pursuant to which the Equity PIPE Subscribers purchased shares of the Common Stock;

### WHEREAS
, ParentCo, SPAC and the Convertible Note PIPE Subscribers have entered into that certain Convertible Note Subscription Agreement, dated as of November 28, 2022 (the “

#### Convertible Note Subscription Agreement
”), pursuant to which the Convertible Note PIPE Subscribers purchased convertible notes of ParentCo (the “

#### Convertible Notes
”) that are convertible into shares of the Common Stock pursuant to the terms of such Convertible Notes;

### WHEREAS
, the Company and the Holders desire to amend the Original Agreement in the form of this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement.

#### NOW
,

### THEREFORE
, in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby

<div align='center'>H-1</div>

TABLE OF CONTENTS

acknowledged, the parties hereto, intending to be legally bound, hereby agree to amend and restated the Original Agreement in its entirety as follows:

## ARTICLE I

### DEFINITIONS
1.1 Definitions . The terms defined in this Article I shall, for all purposes of this Agreement, have the respective meanings set forth below:

“

#### Adverse Disclosure
” shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the principal executive officer or principal financial officer of the Company, after consultation with counsel to the Company, (i) would be required to be